Environmental factors Dysregulated immune response

Slides:



Advertisements
Similar presentations
Tolerance, autoimmunity and the pathogenesis of immune-mediated inflammatory diseases Abul K. Abbas UCSF.
Advertisements

Hannover Medical School February 15 th 2010 The gut microbiota shapes intestinal immune response during health and disease Round and Mazmanian, Nature.
Crohn’s disease - A Review of Symptoms and Treatment
Ulcerative Colitis. Which of the following would not be associated with UC Toxic megacolon Granulomas Pseudopolyps Primary sclerosing cholangitis.
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
Immunotolerance Christoph Mueller
DAREDEVILS: Prajwal Acharya, Cristina Johnson, Julie David, Jen Masciovecchio, Yen Phan.
Inflammatory Bowel Disease Francisco A. Sylvester, MD Associate Professor of Pediatrics.
Musketeers Course October The Mucosal Immune System The organization of the mucosal immune systemThe organization of the mucosal immune system The.
 Asthma  Allergens  Rheumatoid Arthritis  Inflammatory Bowel Disease  Crohn’s disease  Ulcerative Colitis.
Crohn’s Disease & Mycobacterial Infections Kimberly Persley, MD October 19, 2005.
Immunological Disease of the Gastrointestinal Tract
The Digestive System: Crohns disease
Effector T Cell Subsets, Cytokines
Page  2 Accutane, a medication used to treat acne, has recently been linked to dangerous health conditions such as inflammatory bowel disease (IBD).
GI Pathophysiology Jaeyoung Chun, M.D. Pathophysiology
Rheumatoid Arthritis Hayley Evans, CMCBI, King’s College London, UK
IMMUNE RESPONSE AT MUCOSAL SURFACES
Immunity in the Gut Andrew M. Platt, University of Glasgow, UK
Ulcerative colitis andTrichuris infection
Systemic Lupus Erythematosus (SLE)
Dendritic Cells: Migration
Dendritic Cells: Tissue-specific
MicroRNA-146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis Oncotarget, Vol. 6, No. 30 September 10,
Inflamm Intest Dis 2016;1: DOI: /
Autoimmunity: Introduction
B Cells: Regulatory (Bregs)
Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era  Geoffrey A. Preidis, James.
Proposed pathogenesis of inflammatory bowel disease and target sites for pharmacological intervention. Shown are the interactions among bacterial antigens.
Innate immunity in the large intestine
Regulatory T cells & parasites: therapeutic potential
CD46: role in multiple sclerosis
Volume 145, Issue 2, Pages (August 2013)
Acute Graft-versus-Host Disease: Novel Biological Insights
Duane R. Wesemann, Cathryn R. Nagler  Immunity 
Targeting the Human Microbiome With Antibiotics, Probiotics, and Prebiotics: Gastroenterology Enters the Metagenomics Era  Geoffrey A. Preidis, James.
Microbial Influences in Inflammatory Bowel Diseases
Gut Microbiota: Mining for Therapeutic Potential
Metagenomics and Personalized Medicine
Daniel A. Peterson, Daniel N. Frank, Norman R. Pace, Jeffrey I. Gordon 
Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Benoit Chassaing, Arlette Darfeuille–Michaud  Gastroenterology 
Reprint of: Acute Graft-versus-Host Disease: Novel Biological Insights
Warren Strober, Ivan J. Fuss  Gastroenterology 
The Intestinal Immune System in Obesity and Insulin Resistance
Figure 2 Pro-inflammatory and anti-inflammatory effects of the gut microbiota Figure 2 | Pro-inflammatory and anti-inflammatory effects of the gut microbiota.
Advances and Perspectives in the Genetics of Inflammatory Bowel Diseases  Mathias Chamaillard, Razvan Iacob, Pierre Desreumaux, Jean–Frederic Colombel 
Host Defence Peptides B cell
The Virome in Host Health and Disease
John T. Chang, William J. Sandborn  Gastroenterology 
Bridging immunity and lipid metabolism by gut microbiota
Homeostatic Immunity and the Microbiota
Mechanisms of Disease: Inflammatory Bowel Diseases
Getting the Bugs out of the Immune System: Do Bacterial Microbiota “Fix” Intestinal T Cell Responses?  Janet Chow, Sarkis K. Mazmanian  Cell Host & Microbe 
Role of the Microbiota in Immunity and Inflammation
Translating Inflammatory Bowel Disease Research into Clinical Medicine
The Role of TIM-4 in Food Allergy
The gastrointestinal mucosa in health, CDI, and UC
Dan R. Littman, Eric G. Pamer  Cell Host & Microbe 
Daniel A. Peterson, Daniel N. Frank, Norman R. Pace, Jeffrey I. Gordon 
Introduction of Inflammatory bowel disease-Crohn’s disease
Route Connection: Mouth to Intestine in Colitis
NOD1 and NOD2: Signaling, Host Defense, and Inflammatory Disease
Metagenomics and Personalized Medicine
Regulatory T Cells in Asthma
Learning Tolerance while Fighting Ignorance
Steven G. Deeks, Russell Tracy, Daniel C. Douek  Immunity 
Genetic Factors and the Intestinal Microbiome Guide Development of Microbe-Based Therapies for Inflammatory Bowel Diseases  Louis J. Cohen, Judy H. Cho,
Clara Abraham, Ruslan Medzhitov  Gastroenterology 
Presentation transcript:

Environmental factors Dysregulated immune response CATEGORY: IMMUNE DYSFUNCTION INFLAMMATORY BOWEL DISEASE Inflammatory Bowel Disease Stephanie Mathisen, University of Oxford, UK Inflammatory bowel disease (IBD), comprising Crohn’s disease (CD) and ulcerative colitis (UC), is a chronic, relapsing-remitting inflammatory disorder of the gastrointestinal (GI) tract. CD and UC vary in the region of the GI tract they affect; the extent of inflammation and resulting tissue damage; and their associated symptoms. UC tends to exhibit continuous superficial inflammation which spreads from the rectum and is limited to the colon (large intestine), with bloody diarrhoea as the most common symptom. Inflammation associated with CD is transmural (affects all layers of GI tract tissue), patchy (areas of inflammation are interspersed with healthy unaffected tissue) and can present anywhere along the entire GI tract and, in some cases, in the skin and joints. The symptoms of CD are more diverse than for UC, including diarrhoea, abdominal pain and weight loss. The exact cause of IBD is unclear. There appear to be four main factors which influence the disease: host genetic susceptibility, a dysregulated immune response and impairment of intestinal epithelial barrier function, and environmental factors (Figure 1). © The copyright for this work resides with the author Genetic susceptibility Genome-wide association studies (GWASs) have identified a number of genetic loci associated with IBD, including genes specific to either CD or UC, and some which are common to both (Figure 2). The risk of developing IBD conferred by variants at each locus is small for all but a few genes (e.g. IL10RA and IL10RB). It may be the case that IBD only occurs when multiple genetic variations associated with the disease are present. Another possibility is that environmental factors are required to trigger the onset of disease in genetically susceptible individuals. Host genetics IBD Environmental factors Commensals Pathogens Antibiotics, diet, stress Dysregulated immune response Barrier function Figure 1. Factors internal and external to the host that influence inflammatory bowel disease (IBD). Environmental factors Environmental factors such as the commensal microflora, pathogenic infections and metabolic factors are thought to play a role in the development and perpetuation of IBD. The intestinal microbiota, which is dominated by bacteria, but also includes viruses, fungi and protozoa, is crucial for development of the host immune system but also appears to be the target of the inflammatory response during IBD. The composition of the intestinal microbiota appears to be altered during disease, although whether this causes, or results from, intestinal inflammation is unclear. The effects of antibiotics, pathogenic infections and diet on IBD might be explained by their impact on the commensal microflora. CD UC NOD2, NLRP3, ATG16L1, IRGM, CCR6, ICOSL, PTGER4, ITLN1 IL23R, IL12B, JAK2, STAT3, TLR4, CARD9, IRF5, PTPN2/22, TNFAIP3, IL18RAP, LRRK2, TNFSF15, TNFRSF6B IL10, ARPC2, ECM1 Figure 2. Genes associated with Crohn’s disease (CD), ulcerative colitis (UC) or both forms of IBD, from recent genome-wide association studies and their meta-analyses. Continued next page…

Inflammatory Bowel Disease cont. CATEGORY: IMMUNE DYSFUNCTION INFLAMMATORY BOWEL DISEASE Inflammatory Bowel Disease cont. Dysregulated immune response IBD is an immune-mediated disease, but is not considered to involve autoimmunity. The intestine contains an enormous antigenic load derived from the food and microbial flora present. Of the approximately 1014 bacteria in the intestines, the majority are harmless commensals which are beneficial to our health in numerous ways such as aiding digestion and preventing the colonisation of pathogenic species. The intestinal immune system is separated from this luminal content by a single epithelial cell layer, and must initiate the appropriate response – tolerance or protective immunity – upon exposure to each antigen. IBD is thought to arise when an inappropriate immune response is mounted against commensal bacteria. GWASs and experimental results have indicated a number of facets to this dysregulation, for example pro-inflammatory pathways driven by IL-23, decreased immune regulatory mechanisms, and defective barrier function of the intestinal epithelium. Figure 3 shows some key cell populations and mediators thought to be involved in intestinal inflammation. Monoclonal antibody-mediated blockade of the pro-inflammatory cytokine TNFα is very effective at reducing disease in many cases of IBD, highlighting a key role for this molecule in intestinal inflammation. Patients with disease refractory to this treatment, which is only employed after the failure of other therapies such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and immunosuppressants, necessitate the discovery and development of novel therapeutic strategies. © The copyright for this work resides with the author Commensal bacteria Pathogenic TReg Th1 ILC TNFα IL-1β IL-6 Th2 Th17 IL-23 IL-17 IL-22 Mφ DC IL-12 IL-10 TGFβ IFNγ IL-4 IL-5 IL-13 IEC sIgA Figure 3. Key cellular populations and mediators in intestinal homeostasis and the pathogenesis of inflammatory bowel disease. DC, dendritic cell; IEC, intestinal epithelial cell; ILC, innate lymphoid cell; Mφ, macrophage; sIgA, secretory IgA; Th, helper T cell; TReg, regulatory T cell. Key references Maloy and Powrie. 2011. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. Kaser, Zeissig and Blumberg. 2010. Inflammatory Bowel Disease. Annu. Rev. Immunol.